An mRNA vaccine with broad-spectrum neutralizing protection against Omicron variant sublineages BA.4/5 -included SARS-CoV-2

Signal Transduct Target Ther. 2022 Oct 11;7(1):362. doi: 10.1038/s41392-022-01207-4.

Authors

Ye Sang^#^{1

2}, Zhen Zhang^#^{1

2}, Entao Li^#³, Haitao Lu¹, Jinrong Long¹, Yiming Cao¹, Changxiao Yu¹, Tiecheng Wang⁴, Jing Yang⁵, Shengqi Wang⁶

Affiliations

¹ Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China.
² School of Life Science, University of Hebei, Baoding, 071002, China.
³ Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130000, China.
⁴ Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130000, China. wgcha@163.com.
⁵ Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China. jingyang0511@sina.com.
⁶ Beijing Institute of Microbiology and Epidemiology, Beijing, 100850, China. sqwang@bmi.ac.cn.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19* / prevention & control
Humans
SARS-CoV-2* / genetics
Vaccines, Synthetic / genetics
mRNA Vaccines

Substances

Vaccines, Synthetic
mRNA Vaccines

Supplementary concepts

SARS-CoV-2 variants